Short-Term Metformin Protects Against Glucocorticoid-Induced Toxicity in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial [0.03%]
二甲双胍短期干预可对抗糖皮质激素引起的健康志愿者内毒素血症：随机、双盲、安慰剂对照试验
Susanne Thierry,Caspar Joyce Peterson,Stéphanie Pfammatter et al.
Susanne Thierry et al.
Objective: Glucocorticoids (GCs) are potent anti-inflammatory drugs, but strategies to prevent side effects are lacking. We investigated whether metformin could prevent GC-related toxicity and explored the underlying mech...
Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study [0.03%]
糖尿病代谢功能障碍相关脂肪肝病晚期纤维化筛查的前瞻性多中心研究
Cyrielle Caussy,Bruno Vergès,Damien Leleu et al.
Cyrielle Caussy et al.
Objective: Screening for advanced fibrosis (AF) resulting from metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in diabetology. This study aimed to compare the performance of noninvasive tes...
In-Hospital Diabetes Management by a Diabetes Team and Insulin Titration Algorithms Based on Continuous Glucose Monitoring or Point-of-Care Glucose Testing in Patients With Type 2 Diabetes (DIATEC): A Randomized Controlled Trial [0.03%]
基于持续葡萄糖监测或即时血糖检测的胰岛素调整算法和糖尿病团队管理对2型糖尿病患者的住院治疗效果研究（DIATEC）：一项随机对照试验
Mikkel T Olsen,Carina K Klarskov,Signe H Jensen et al.
Mikkel T Olsen et al.
Objective: The DIATEC trial investigates the glycemic and clinical effects of inpatient continuous glucose monitoring (CGM)-guided insulin titration by diabetes teams. ...
Wave in Pediatric Type 1 Diabetes Incidence After the Emergence of COVID-19: Peak and Trough Patterns in German Youth-A Population-Based Study From the Prospective Multicenter DPV Registry [0.03%]
新冠肺炎疫情出现后德国儿童1型糖尿病发病率波动：基于前瞻性多中心DPV登记系统的流行病学研究
Clemens Kamrath,Alexander J Eckert,Sarah Lignitz et al.
Clemens Kamrath et al.
Islet Autoantibody Screening Throughout Australia Using In-Home Blood Spot Sampling: 2-Year Outcomes of Type1Screen [0.03%]
基于家庭的指尖血样本筛查胰岛自身抗体在澳大利亚全国范围内的应用及糖尿病预防项目（DPP）适应性研究两年随访结果：Type1Screen项目
John M Wentworth,Anna B E Sing,Gaetano Naselli et al.
John M Wentworth et al.
Objective: Type1Screen offers islet autoantibody testing to Australians with a family history of type 1 diabetes (T1D) with the dual aims of preventing diabetic ketoacidosis (DKA) and enabling use of disease-modifying the...
New Therapeutic Perspectives in Type B Insulin Resistance Syndrome: Efficacy of a Multitarget Therapy With Obinutuzumab and Mycophenolate Mofetil in Two Patients With Insulin Receptor Autoantibodies and Systemic Lupus Erythematosus [0.03%]
B型胰岛素抵抗综合征的新治疗观点：利妥昔单抗联合霉酚酸酯治疗2例自身免疫性胰岛素受体抗体阳性系统性红斑狼疮患者疗效观察
Vincent Jachiet,Philippine Vuillaume,Jérôme Hadjadj et al.
Vincent Jachiet et al.
Longitudinal Associations of PFAS Exposure With Insulin Sensitivity and β-Cell Function Among Hispanic Women With Gestational Diabetes Mellitus History [0.03%]
妊娠糖尿病史的西班牙裔女性中PFAS暴露与胰岛素敏感性和β细胞功能纵向关联的研究
Ni Kang,Wu Chen,Nosa Osazuwa et al.
Ni Kang et al.
Objective: We investigated associations between per- and polyfluoroalkyl substances (PFAS) and changes in diabetes indicators from pregnancy to 12 years after delivery among women with a history of gestational diabetes me...
Kirsten J Cromie,Robert D Murray,Ramzi A Ajjan et al.
Kirsten J Cromie et al.
Objective: Diabetes is a potential late consequence of childhood and young adult cancer (CYAC) treatment. Causative treatments associated with diabetes have been identified in retrospective cohort studies but have not bee...
Erratum. 7. Diabetes Technology: Standards of Care in Diabetes-2025. Diabetes Care 2025;48(Suppl. 1):S146-S166 [0.03%]
糖尿病技术：《糖尿病诊疗标准-2025》第7条。Diabetes Care 2025;48(补充号1)：S146-S166 Erratum
American Diabetes Association Professional Practice Committee
American Diabetes Association Professional Practice Committee
In Table 7.2, "Common interfering substances and/or conditions that affect glucose meters (for inpatient and outpatient use)," of the article cited above, the effects on glucose values measured by blood glucose meters for high and low hemat...
Published Erratum
Diabetes care. 2025 Jan 23:dc25er04b. DOI:10.2337/dc25-er04b 2025